Self-delivering RNAi Immunotherapy PH-762 Silences PD-1 for Antitumor Efficacy
Author Information
Author(s): Cuiffo Benjamin, Maxwell Melissa, Yan Dingxue, Guemiri Ramdane, Boone Andrew, Bellet Deborah, Rivest Brianna, Cardia James, Robert Caroline, Fricker Simon P.
Primary Institution: Phio Pharmaceuticals
Hypothesis
Can PH-762, a self-delivering RNAi therapeutic, effectively silence PD-1 to enhance antitumor immunity?
Conclusion
PH-762 shows promise as a neoadjuvant immunotherapy candidate by effectively silencing PD-1 and generating both local and systemic antitumor effects.
Supporting Evidence
- PH-762 was rapidly internalized by human T cells, silencing PD-1 mRNA and decreasing PD-1 surface protein.
- IT mPH-762 provided robust antitumor efficacy and was well tolerated in murine models.
- IT mPH-762 demonstrated efficacy against untreated distal tumors, indicating an abscopal effect.
Takeaway
This study tested a new treatment that helps the immune system fight cancer by turning off a protein called PD-1, which can stop immune cells from working.
Methodology
The study involved in vitro and in vivo experiments using murine tumor models to evaluate the pharmacology and antitumor efficacy of PH-762.
Limitations
The study is preclinical and results may not directly translate to human patients.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website